


CY 208-243

Cat. No.:	HY-106094		
CAS No.:	100999-26-6		
Molecular Formula:	C ₁₉ H ₁₈ N ₂		
Molecular Weight:	274.36		
Target:	Dopamine Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (182.24 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.6448 mL	18.2242 mL	36.4485 mL
	5 mM	0.7290 mL	3.6448 mL	7.2897 mL
	10 mM	0.3645 mL	1.8224 mL	3.6448 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CY 208-243 is a selective dopamine D1 receptor agonist which exhibits antiparkinsonian activity^[1].

IC₅₀ & Target

D₁ Receptor

In Vivo

Pretreatment with CY 208-243 (2.5 mg/kg; s.c.) prevents the increase of DA release and metabolism induced by the D-1 antagonist, SCH 23390 (0.05 mg/kg; s.c.)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (180-200 g) ^[1]
Dosage:	2.5 mg/kg
Administration:	Subcutaneous
Result:	Prevented the increase of DA release and metabolism induced by the D-1 antagonist.

REFERENCES

- [1]. Imperato A, et al. CY 208-243, a novel dopamine D-1 receptor agonist, fails to modify dopamine release in freely moving rats. *Eur J Pharmacol.* 1989 Jan 24;160(1):155-8.
- [2]. Temlett JA, et al. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. *Eur J Pharmacol.* 1988 Nov 1;156(2):197-206.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA